Pictet Asset Management Sa Chinook Therapeutics, Inc. Transaction History

Pictet Asset Management Sa

$83.4 Billion
Q2 2023

A detailed history of Pictet Asset Management Sa transactions in Chinook Therapeutics, Inc. stock. As of the latest transaction made, Pictet Asset Management Sa holds 22,829 shares of KDNY stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,829

Previous 1,174,756 98.06%

Holding current value

Previous $27.2 Million 96.78%

% of portfolio

0.0%

Previous 0.03%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$18.66 - $38.58 $21.5 Million - $44.4 Million	-1,151,927 Reduced 98.06%	22,829 $877,000
Q1 2023 May 10, 2023	BUY	$21.53 - $26.8 $184,985 - $230,265	8,592 Added 0.74%	1,174,756 $27.2 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $9.02 Million - $13.2 Million	484,052 Added 70.96%	1,166,164 $30.6 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $11.9 Million - $15.9 Million	682,112 New	682,112 $13.4 Million

Others Institutions Holding KDNY

# of Institutions

Shares Held

234K

Call Options Held

Put Options Held

View Full List

About CHINOOK THERAPEUTICS, INC.

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

More about KDNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Sa with notifications on news.

Account

Pictet Asset Management Sa Chinook Therapeutics, Inc. Transaction History